James S Goydos1, David H Gorski. 1. Division of Surgical Oncology, UMDNJ-Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, New Brunswick, New Jersey 08901, USA.
Abstract
PURPOSE: Vascular endothelial growth factor (VEGF)-C promotes the ingrowth and invasion of lymphatics in many different tumor types, including melanoma. To determine whether expression of VEGF-C correlates with stage of progression, we measured VEGF-C mRNA levels in melanomas representing different stages of progression and from the vertical and horizontal growth-phase of individual primary melanomas. EXPERIMENTAL DESIGN: Total RNA was extracted from human melanoma specimens taken from operative specimens and subjected to quantitative real-time PCR. VEGF-C levels were determined for 54 melanoma samples, including primary melanomas (n=15), local recurrences (n=6), regional dermal metastases (n=11), nodal metastases (n=12), and distant metastases (n=10). As a surrogate for lymphatic density, we also measured the expression of the lymphatic endothelial marker LYVE-1 and correlated its expression with previously measured VEGF-C levels. RESULTS: Vertical growth phase melanomas expressed significantly higher levels of VEGF-C than horizontal growth phase melanomas. Nodal metastases expressed the highest level of VEGF-C, followed by regional dermal metastases. Primary and local recurrences expressed a relatively low level of VEGF-C, as did negative lymph nodes and distant metastases. In addition, VEGF-C expression correlated well with LYVE-1 expression (r=0.611; P<0.0001). CONCLUSIONS: These data suggest that high levels of VEGF-C may be important in regional lymphatic disease in melanoma and that VEGF-C and LYVE-1 levels may identify tumors with a high risk for nodal metastases, for which antilymphangiogenic therapy may be more effective.
PURPOSE:Vascular endothelial growth factor (VEGF)-C promotes the ingrowth and invasion of lymphatics in many different tumor types, including melanoma. To determine whether expression of VEGF-C correlates with stage of progression, we measured VEGF-C mRNA levels in melanomas representing different stages of progression and from the vertical and horizontal growth-phase of individual primary melanomas. EXPERIMENTAL DESIGN: Total RNA was extracted from humanmelanoma specimens taken from operative specimens and subjected to quantitative real-time PCR. VEGF-C levels were determined for 54 melanoma samples, including primary melanomas (n=15), local recurrences (n=6), regional dermal metastases (n=11), nodal metastases (n=12), and distant metastases (n=10). As a surrogate for lymphatic density, we also measured the expression of the lymphatic endothelial marker LYVE-1 and correlated its expression with previously measured VEGF-C levels. RESULTS: Vertical growth phase melanomas expressed significantly higher levels of VEGF-C than horizontal growth phase melanomas. Nodal metastases expressed the highest level of VEGF-C, followed by regional dermal metastases. Primary and local recurrences expressed a relatively low level of VEGF-C, as did negative lymph nodes and distant metastases. In addition, VEGF-C expression correlated well with LYVE-1 expression (r=0.611; P<0.0001). CONCLUSIONS: These data suggest that high levels of VEGF-C may be important in regional lymphatic disease in melanoma and that VEGF-C and LYVE-1 levels may identify tumors with a high risk for nodal metastases, for which antilymphangiogenic therapy may be more effective.
Authors: Vasileia-Ismini Alexaki; Delphine Javelaud; Leon C L Van Kempen; Khalid S Mohammad; Sylviane Dennler; Flavie Luciani; Keith S Hoek; Patricia Juàrez; James S Goydos; Pierrick J Fournier; Claire Sibon; Corine Bertolotto; Franck Verrecchia; Simon Saule; Veronique Delmas; Robert Ballotti; Lionel Larue; Philippe Saiag; Theresa A Guise; Alain Mauviel Journal: J Natl Cancer Inst Date: 2010-07-21 Impact factor: 13.506
Authors: Kathryn A Tworkoski; James T Platt; Antonella Bacchiocchi; Marcus Bosenberg; Titus J Boggon; David F Stern Journal: Pigment Cell Melanoma Res Date: 2013-05-21 Impact factor: 4.693
Authors: Carolina Salvador; Bing Li; Richard Hansen; Daniel E Cramer; Maiying Kong; Jun Yan Journal: Clin Cancer Res Date: 2008-02-15 Impact factor: 12.531
Authors: Ramin Shayan; Rachael Inder; Tara Karnezis; Carol Caesar; Karri Paavonen; Mark W Ashton; G Bruce Mann; G Ian Taylor; Marc G Achen; Steven A Stacker Journal: Clin Exp Metastasis Date: 2012-11-03 Impact factor: 5.150